Claus Bachert, M.D., was the principal investigator of the SINUS-24 and SINUS-52 phase 3 trials, the results of which led to the FDA approval of Dupixent for use with other medicines to treat chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease...